Communique of GTTAC Meeting of 20-21 Feb 2017
This Communiqué covers matters considered at the 51st meeting of the Gene Technology Technical Advisory Committee (20 & 21 February 2017, Canberra).
Licence application DIR 148 from Sanofi-Aventis Australia Pty Ltd is for the import, transport, storage and disposal of a live GM dengue vaccine, Dengvaxia, as part of its commercial supply in Australia. GTTAC was informed that the Therapeutic Goods Administration (TGA) will assess quality, safety and efficacy of the vaccine.
GTTAC noted the key points in the consultation RARMP including the conclusion that this release poses negligible risks to the health and safety of people and the environment as a result of gene technology.